Hi S***y, I’m J***e, a recruiter at StrategyBrain. I was impressed by your two decades of leadership at P***r,especially your track record in M&A, licensing and corporate development. We’re partnering with B***s to find a Senior Vice President of Corporate Development and Strategic Partnerships. Would you be open to a brief chat to explore this opportunity?

Hi S***y, great to hear from you,and thank you for your interest. B***s is a fast-growing biotech innovator in immunology, and the SVP, Corporate Development & Strategic Partnerships role sits on the executive leadership team. In this role you would: • Lead and execute global M&A, equity investments and divestiture strategies from target identification through post-merger integration. • Structure and negotiate high-value licensing, collaboration and joint-venture agreements with industry partners and financial sponsors. • Advise the CEO and Board on valuation, deal structuring and value-creation opportunities. • Build and mentor a world-class corporate development team to drive cross-functional alignment and execution. • Monitor market trends and competitive landscapes to uncover strategic growth and partnership opportunities. With your 20 years at P***r driving M&A, licensing and corporate development, you’d immediately shape our strategic roadmap and help accelerate breakthrough therapies to market. B***s offers a highly collaborative culture, global resources, and a competitive compensation package with equity upside. Does this capture what you’re looking for? I’d love to dive deeper,are you available for a 30-minute call tomorrow at 10:00 AM ET or Thursday at 2:00 PM ET? Let me know what works best, or feel free to suggest another time.

Hi S***y, Great questions. On the equity side, B***s offers a meaningful ownership stake at the SVP level: you’d receive an upfront grant of stock options (or RSUs) that vest over four years (with a one-year cliff), plus periodic, performance-based refreshers tied to key pipeline and business milestones. In combination with base salary and bonus, the package is designed to deliver significant upside as our immunology programs advance. Regarding hybrid work, we’ve adopted a flexible model,typically 2,3 days per week in our New York hub (or global office) for team collaboration and strategy sessions, with the balance fully remote. We also accommodate travel for investor meetings, conferences and key offsites. Thursday at 2:00 PM ET works perfectly. I’ll send a calendar invite shortly. Looking forward to diving deeper!

Hi S***y, Great questions. For equity refreshers, we tie them to both pipeline and business milestones,think key clinical inflection points (e.g., IND clearance, Phase II/III trial initiations or readouts), first patient dosing in pivotal studies, and commercial milestones such as initial drug approvals or launch ramp. On the business side, hitting strategic partnership or licensing deal close dates, hitting agreed revenue or co‐development funding thresholds, and successful divestitures can also trigger refresh grants. As for travel, beyond investor roadshows and our annual offsite, you’d expect roughly 20,30% travel,typically 1,2 days per month. That covers partner site visits (biotech collaborators, financial sponsors), due diligence trips for M&A targets, key industry conferences, and occasional global leadership summits. I’ll send over a Thursday 2:00 PM ET invite shortly. Looking forward to diving deeper then!

Hi S***y, Great question. While exact numbers vary based on performance and milestone achievement, at the SVP level our equity refreshers typically fall in the 25,35% range of your initial grant each year. In standout years,when you hit major clinical inflection points or close a strategic partnership,you can see refresh grants up toward 40,50% of that original award. We’ll of course tie the final numbers to our agreed milestones and your role’s scope. Looking forward to walking through the full comp framework on Thursday at 2 PM ET. Talk soon! Best, J***e

Hi S***y, Our refresh grants are typically approved at the start of our fiscal year (January) and vest over the following 12 months. For the standard refresh, we vest in equal quarterly installments (25% each quarter) to keep alignment throughout the year. Performance‐based refreshers tied to key milestones are slightly front-loaded,roughly 30% vests in the first half once early pipeline or deal milestones are hit, with the remaining 70% vesting in Q3/Q4 as full objectives are met. I’ll walk you through exact dates and sample schedules on our Thursday call. Looking forward to it! Best, J***e